Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

aventis pharma aebe - buserelin - ΚΟΝΙΣ ΚΑΙ ΔΙΑΛΥΤΗΣ ΓΙΑ ΕΝΕΣΙΜΟ ΕΝΑΙΩΡΗΜΑ - 3.6mg/pf.syr - ΦΑΡΜΑΚΕΥΤΙΚΟ ΠΡΟΪΟΝ

Ευρωπαϊκή Ένωση - Ελληνικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - το imatinib - precursor cell lymphoblastic leukemia-lymphoma; dermatofibrosarcoma; myelodysplastic-myeloproliferative diseases; leukemia, myelogenous, chronic, bcr-abl positive; hypereosinophilic syndrome - το imatinib - imatinib accord is indicated for the treatment of- adult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. - adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. - adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. - adult patients with relapsed or refractory ph+ all as monotherapy. - adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. - adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. - adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. - the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). - the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. patients who have a low or very low risk of recurrence should not receive adjuvant treatmentthe effect of imatinib on the outcome of bone marrow transplantation has not been determined. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. Εκτός από τη νεοδιαγνωσθείσα ΧΜΛ σε χρόνια φάση, δεν υπάρχουν ελεγχόμενες μελέτες που να καταδεικνύουν κλινικό όφελος ή αυξημένη επιβίωση για αυτές τις ασθένειες. .

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - minocycline hydrochloride - capsule,hard - 50mg - minocycline hydrochloride (0013614987) 53,98mg - minocycline

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - glimepiride - tablets - 1mg - glimepiride (0093479971) 1mg - glimepiride

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - glimepiride - tablets - 2mg - glimepiride (0093479971) 2mg - glimepiride

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - glimepiride - tablets - 3mg - glimepiride (0093479971) 3mg - glimepiride

Κύπρος - Ελληνικά - Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

delorbis pharmaceuticals ltd (0000009620) 17 athinon street, ergates industrial area, lefkosia, 2081, 28629 - glimepiride - tablets - 4mg - glimepiride (0093479971) 4mg - glimepiride

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

castalia laboratoires dermatologiques, ΕΛΛΑΔΑ (0000006071) Αγ. Μαρίνας, Παιανία Αττικής - doxycycline hyclate - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 100mg/cap - 0024390145 doxycycline hyclate 115.400000 mg - doxycycline

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

castalia laboratoires dermatologiques, ΕΛΛΑΔΑ (0000006071) Αγ. Μαρίνας, Παιανία Αττικής - doxycycline hyclate - ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ - 50mg/cap - 0024390145 doxycycline hyclate 57.700000 mg - doxycycline

Ελλάδα - Ελληνικά - Εθνικός Οργανισμός Φαρμάκων

teofarma srl, italy via f. lli cervi 8, i-27010 valle salimbene (pv) 0039 0382 4220 08 - minocycline hydrochloride - caps (ΚΑΨΑΚΙΟ, ΣΚΛΗΡΟ) - 50mg/cap - minocycline hydrochloride 53,984mg - minocycline